Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia
GSK and GEN announced today top line results from the concluded pivotal trial.
-
Image of new antibiotic in action opens up new opportunities to combat antibacterial resistance
Pictures have been published showing how a type of experimental antibiotic can kill bacteria already resistant to existing treatments.
-
GSK exercises option on Anacor’s novel antibiotic for the treatment of gram-negative infections
GSK and Anacor Pharmaceuticals today announced that GSK has exercised its option to obtain an exclusive licence to develop.
-
GSK receives CHMP positive opinion for a new indication for Arixtra
GSK today announced that CHMP has issued a positive opinion for Arixtra (fondaparinux),an anti-clotting drug (antithrombotic).
-
GlaxoSmithKline statement in response to FDA announcement on TIDE trial
GSK confirmed that it will suspend enrollment of new patients in TIDE clinical trial at the request of FDA.
-
GSK announces Q2 results for 2010
Q2 EPS before major restructuring* 2.6p (29.3p excluding pre-announced legal charge)
-
GlaxoSmithKline legal update
GSK today announces that it expects to record a legal charge for the second quarter of 2010 of £1.57billion ($2.36 billion).
-
GlaxoSmithKline statement in response to FDA Advisory Committees’ vote on safety of Avandia® (rosiglitazone)
GSK confirmed that a joint advisory committee to the FDA voted to allow Avandia to remain on the market.
-
GlaxoSmithKline (GSK) responds to Senate Finance Committee letter of 12 July to FDA
The Senate Finance Committee (SFC) has released a small subset of the 14 million pages of documents provided to plaintiffs&apos.
-
Data support Avandia (rosiglitazone maleate) cardiovascular safety profile
The U.S. Food and Drug Administration (FDA) today posted a comprehensive review conducted by GlaxoSmithKline (GSK).
-
GSK EU regulatory update on Avandia (rosiglitazone)
GSK today confirmed that on behalf of EMA, the CHMP is to review the benefit/risk profile of Avandia (rosiglitazone).
-
GSK and EDB commit $35 million (USD) in funding to support research in green and sustainable manufacturing in Singapore
GSK and the Singapore EDB, the government agency responsible for economic growth and development.
-
GlaxoSmithKline and Genmab announce amendment to Ofatumumab agreement
GSK and GEN announced today an amendment to the ofatumumab co-development and commercialisation agreement.
-
GlaxoSmithKline creates a new operating unit dedicated to expanding access to medicines for people living in the world’s poorest countries
As part of its commitment to further transform the companys approach to diseases that disproportionately affect the world's poorest people.
-
GSK and Aptuit finalise agreement for Aptuit to acquire GSK’s research operations in Italy
Augments Aptuit's global, integrated scientific and operational capabilities and preserves scientific expertise at the centre
-
GlaxoSmithKline receives EU authorisation for a new therapeutic indication for Tyverb® (lapatinib)
GSK confirmed that EC has granted a variation to the conditional marketing authorisation for Tyverb in the EU for therapeutic indication.
-
GlaxoSmithKline enters agreement with Medivir for exclusive rights to cold sore treatment Xerclear™
GlaxoSmithKline (GSK) and Medivir (STO: MVIR-B) today announced an exclusive agreement for the commercialisation of cold sore treatment.
-
GlaxoSmithKline receives conditional marketing authorisation in the EU for Votrient® (pazopanib)
As part of these conditions, GSK will provide data from ongoing clinical studies.
-
FDA approves Jalyn™, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate
BPH is one of the most common prostate disorders, affecting nearly half of all men 50 years of age or older in the U.S.
-
GlaxoSmithKline Receives Complete Response from FDA for Candidate Meningococcal and Hib Combination Vaccine
Meningococcal and Hib diseases are caused by potentially deadly bacteria that can lead to meningitis and other very serious complications.
